No Detail Found!

Clinicohaematological Characteristics, Cytogenetic Profile, and Risk Strati cation in Myelodysplastic Syndrome: A Study from Pakistan

Author(s)
Alia Waheed Department of Haematology, Armed Forces Institute of Pathology,Rawalpindi,Pakistan; Department of Haematology, National University of Medical Sciences,Rawalpindi,Pakistan
Saleem Ahmed Khan Department of Haematology, National University of Medical Sciences,Rawalpindi,Pakistan
Ayesha Khursheed Department of Haematology, Armed Forces Institute of Pathology,Rawalpindi,Pakistan
Rafia Mahmood Department of Haematology, Armed Forces Institute of Pathology,Rawalpindi,Pakistan
Humayoon Shaque Satti Department of Bioinformatics, National University of Medical Sciences,Rawalpindi,Pakistan
Hamid Saeed Malik Department of Haematology, Armed Forces Institute of Pathology,Rawalpindi,Pakistan
Abstract
Objective: To determine the clinicohaematological characteristics, cytogenetic abnormalities, and risk pro les of treatment-naive Pakistani myelodysplastic syndrome (MDS) patients. Study Design: Descriptive study. Place and Duration of the Study: Department of Haematology, Armed Forces Institute of Pathology, Rawalpindi, Pakistan, from June 2019 to 2023. Methodology: MDS was diagnosed following the World Health Organization (WHO) criteria, with detailed documentation of clinicohaematological parameters and cytogenetic ndings. Risk assessment was done using the Revised International Prognostic Scoring System (IPSS-R). Descriptive statistics summarised the patient characteristics, while Chi-square and parametric or non-parametric tests facilitated comparisons. Survival analysis utilised Cox proportional hazard models and Kaplan-Meier survival curves. Results: A total of 47 MDS patients were assessed, with a median age of 66 years (IQR = 20) and a male predominance (68%). Anaemia (haemoglobin <10 g/dL) was the most frequent presentation, observed in 95.7% of patients. MDS with multilineage dysplasia was the most common subtype, diagnosed in 59.6% of cases. Cytogenetic analyses revealed a normal karyotype in 55.3% of patients, while 44.7% revealed clonal abnormalities, including trisomy 8, monosomy 7, and complex karyotypes. Risk strati cation identi ed 40.4% of patients as low-risk at presentation. Conclusion: Cytogenetic analysis showed that a normal karyotype was the most prevalent nding, with low-risk disease predominating in risk strati cation. These ndings provide valuable insights into the clinicohaematological and cytogenetic pro les of MDS patients in the Pakistani population.
Publication Details
Page(s) 162-167
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 35, Issue: 2, Year: 2025

Request the full text from PASTIC

Keywords
Myelodysplastic syndrome, World Health Organization, Cytogenetics, Risk strati cation, Revised international prognostic scoring system
References
Zeidan AM,Platzbecker U,Bewersdorf JP,Stahl M,Ades L,Borate U .2023 .Consensus proposal for revised international working group 2023 response criteria for higher-risk myelodysplastic syndromes. Blood, 10(17) : 2047-61.
Ho FW,Madanat YF .2023 .Molecular drivers of myelodysplastic neoplasms (MDS) classi cation and prognostic relevance. Cells, 10(4) : 627.
Srilakshmi K,Lakshmi DV .2024 .Myelodysplastic syndrome risk assessment using priority linked correlated feature set using ResNet50. Biomed Signal Proc Control, 106597(8) : 106597.
Kewan T,Stahl M,Bewersdorf JP,Zeidan AM .2024 .Treatment of myelodysplastic syndromes for older patients: Current state of science, challenges, and opportunities. Curr Hematol Malig Rep, 10(3) : 151.
Auger N,Guilbert ND,Quessada J,Theisen O,Pochitalo ML,Troadec MB .2023 .Cytogenetics in the management of myelodysplastic neoplasms (myelodysplastic syndromes, MDS): Guidelines from the groupe francophone de cytogenetique hematologique (GFCH). Curr Res Transl Med, 103409(4) : 103409.
Ra N,Khan MH,Sahibzada M,Khan SA,Vijayan AS,Ullah N .2024 .Recent developments and challenges in the treatment of acute leukemia and myelodysplastic syndromes: A systematic review. Cureus, 10(10) : .
Khanna V,Lu R,Kumar J,Stehr H,Spinner MA,Silva O .2022 .Characterization of clinical, molecular, and prognostic features of the WHO 2022 classi cation system for myelodysplastic neoplasms (MDS). Blood, 10 : 6955-7.
Mahmood R,Altaf C,Ahmed P,Khan SA,Malik HS .2017 .Myelodysplastic syndrome in Pakistan: Clinicohematological characteristics, cytogenetic pro le, and risk strati cation. Turk J Haematology, 0130(2) : 109-55.
Arber DA,Orazi A,Hasserjian R,Thiele J,Borowitz MJ,Le Beau MM .2016 .The 2016 revision to the World Health Organization classi cation of myeloid neoplasms and acute leukemia. -03-643544., 10(20) : 2391-405.
Baer C,Huber S,Hutter S,Meggendorfer M,Nadarajah N,Walter W .2023 .Risk prediction in MDS: Independent validation of the IPSS-M ready for routine?. Leukemia, 10(4) : 938-41.
Anwar N,Arshad A,Nadeem M,Khurram S,Fatima N,Sharif S .2017 .cytogenetic pro le of myelodysplastic syndromes in Pakistan-compare and contrast. Mol Cytogenet, 10 : 1-7.
Rashid A,Khurshid M,Shaikh U,Adil S U .2014 .Chromosomal abnormalities in primary myelodysplastic syndrome. J Coll Physicians Surg Pak, 24(9) : 632.
Sultan S,Irfan SM .2016 .Adult primary myelodysplastic syndrome: experience from a tertiary care center in Pakistan. Asian Pac J Can Prev, 17(3) : 1535-7.
Narayanan S. .2017 .Clinical, hematological, and cytogenetic pro le of adult myelodysplastic syndrome in a tertiary care center. J Blood Med, 10 : 21-7.
Voso MT,Fenu S,Latagliata R,Buccisano F,Piciocchi A,Spiriti MAA .2012 .Revised international prognostic scoring system (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes signi cantly better than IPSS and WHO prognostic scoring system: Validation by the gruppo romano mielodisplasie Italian regional database. J Clin Oncol, 48(21) : 2671-7.
Greenberg PL,Tuechler H,Schanz J,Sanz G,Manero GG,Sole F .2012 .Revised international prognostic scoring system for myelodysplastic syndromes. -03-420489., 10(12) : 2454-65.
Chaubey R,Sazawal S,Dada R,Mahapatra M,Saxena R .2011 .Cytogenetic pro le of Indian patients with de novo myelodysplastic syndromes. Indian J Med Res, 134(4) : 452-7.
Wu J,Zhang Y,Qin T,Xu Z,Qu S,Pan L .2022 .IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons e60 years with myelodysplastic syndromes. Exp Hematol Oncol, 10(1) : 73.
Hou HA,Tsai CH,Lin CC,Chou WC,Kuo YY,Liu CY .2018 .Incorporation of mutations in ve genes in the revised international prognostic scoring system can improve risk strati cation in the patients with myelodysplastic syndrome. Blood Can J, 10(4) : 39.
Elnahass Y,Youssif L Y .2018 .Cytogenetic features in primary myelodysplastic syndrome Egyptian patients. J Adv Res, 02 : 77-83.
Li L,Liu X-P,Nie L,Yu M-H,Zhang Y,Qin T-J .2008 .Unique cytogenetic features of primary myelodysplastic syndromes in Chinese patients. Leukemia Res, 11(9) : 1194-8.
0

Citations

0

Downloads

49

Views